✓an ATP-competitive mTOR inhibitor (IC = 0.8 nM) [225]✓reduces p-RPS6 (S235/236) in normal human dermal fibroblasts (NHDFs) [100]✓reduces p-RPS6 (S240/244) in an HRASG12V mutant cell line by blocking the ERK/TSC2 signaling [113]✓reduces p-RPS6 (S235/236) and p-AKT (S473) and induces PD-L1 in cancer cells [150]. This evidence concerns the gene TSC2 and cancer.